Dr. Nana Mainoo, Regulatory Consultant and CEOHeadquartered in Boston with a presence in London, the firm works across therapeutic areas and product types, with a distinctive strength in orphan drug development. More than a regulatory adviser, Cleracs serves as a partner that helps clients advance from early research to market approval with clarity and confidence.
What distinguishes Cleracs is its 360-degree model, which integrates regulatory expertise with clinical and scientific insight and funding guidance, reinforced by strong industry connections. Rather than applying rigid frameworks, the firm adapts to each client’s style, culture and resources. Clients value how seamlessly this expertise fits into their organizations, expanding regulatory and scientific depth without disrupting internal culture.
“Our mission is to move assets forward efficiently, either toward market approval or to the point where the right partner can continue development,” says Dr. Nana Mainoo, regulatory consultant and CEO.
This focus on moving programs with speed and precision is supported by practical guidance at every stage. Cleracs works with clients from preclinical planning onward and advises on early regulatory interactions, including pre-investigational new drug (pre-IND) meetings and trial designs. It then manages the major submissions that follow—investigational new drug (IND) applications, new drug applications (NDA) and biologics license applications (BLA).
For medical device innovators, Cleracs has guided regulatory planning through U.S. food and drug administration (FDA) pathways and achieved conformité européenne (CE) marking under europe’s medical device regulation (MDR). By embedding study endpoints and risk-mitigation measures early, the firm helps reduce rework, maintain timelines and improve the likelihood of a first-cycle approval.
Accelerating Approvals, Reducing Risk
Beyond regulatory execution, Cleracs also advises on the commercial realities that determine whether therapies succeed once approved. Its services include market access and reimbursement planning, with particular expertise in health economics and outcomes research (HEOR), ensuring that orphan drug candidates and novel devices demonstrate both clinical value and economic viability. The firm conducts due diligence for licensing, acquisitions and investment decisions, giving clients confidence as they enter partnerships or seek funding.
Cleracs anticipates regulatory expectations at every milestone, preparing strategies that stand up to scrutiny. After approval, its team remains engaged with pharmacovigilance, compliance oversight and lifecycle management, ensuring therapies continue to meet evolving standards while maintaining patient safety.
-
Our mission is to move assets forward efficiently, either toward market approval or to the point where the right partner can continue development.
Beyond regulatory execution, Cleracs also advises on the commercial realities that determine whether therapies succeed once approved. Its services include market access and reimbursement planning, with particular expertise in health economics and outcomes research (HEOR), ensuring that orphan drug candidates and novel devices demonstrate both clinical value and economic viability. The firm conducts due diligence for licensing, acquisitions and investment decisions, giving clients confidence as they enter partnerships or seek funding.
The results demonstrate the strength of this model. Cleracs has guided NDA approvals through the streamlined 505(b)(2) pathway, filed INDs that enabled human trials and secured U.S. and European medicines agency (EMA) designations including orphan drug, rare pediatric disease, fast track and breakthrough therapy. In several cases, regulatory milestones were paired with fundraising support, enabling clients not only to gain approvals but to secure the resources necessary for commercialization or licensing.
Behind this record of success is a leadership team that brings decades of combined expertise. Alongside Dr. Mainoo, Vicky Demby, PhD, and Pragnesh Donga, RAC, contribute extensive experience in regulatory affairs, clinical development and digital health. Their collective guidance ensures that Cleracs delivers technical expertise as well as a broader vision for how regulatory strategy, development planning and financial alignment must work together.
Ultimately, Cleracs represents more than consulting; it is a committed partnership dedicated to maximizing the value of innovation and ensuring transformative treatments and technologies reach the patients who need them most.
Choosing a Regulatory Consulting Partner in Biotechnology
Biotechnology companies do not hire regulatory consultants simply to prepare documents. They rely on them to help protect development timelines, preserve capital and keep promising therapies, diagnostics or devices moving through increasingly complex regulatory systems. A weak consulting partner may still deliver submissions, but it can leave companies with clinical plans that fail to address agency concerns, milestones that do not support investor expectations or filings that require expensive revisions later.
Biotechnology's regulatory strategy goes well beyond the approval path. It impacts financing, partnering and trial design and eventually, the patients. A proper consulting relationship helps to clarify uncertainty early in the process before it turns into an expensive lag.
Regulatory burden occurs throughout the development continuum, rather than just at the submission. In the early stage, the company has to figure out how to bring the science to an approvable path, with careful selection of indication, endpoints, trial design and agency interaction. This required clinical, non-clinical, manufacturing and commercial requirements to be aligned and to optimize the decision's impact on the late-stage marketing application.
Medical device and digital health companies face additional complexity because classification requirements, evidence standards and post-market expectations can vary significantly across the FDA, Europe and other international regulatory systems. In many cases, companies need guidance that separates genuine scientific risk from avoidable regulatory problems because each affects investor confidence and development planning differently.
The strongest consulting partners become involved early enough to shape the program itself rather than reviewing it after key decisions have already been made. That means helping define the likely path to approval, identifying weak assumptions, preparing for agency interactions and keeping development documentation aligned across the product lifecycle.
The benefit of that advice is more than just accelerating submissions. It's a reduction in unnecessary setbacks, clarity of planning for leadership, and leverage in partnership or licensing talks. Leaders should find advisors that understand how to weave together science, regulation and business timing-not standard, one-size-fits-all strategies.
The relationship also needs to fit the company’s stage, resources and internal working style. Even strong regulatory advice loses value if it cannot be realistically implemented by the teams responsible for development.
Submission experience remains critical, but practical knowledge of agency interaction is equally important. IND, NDA and BLA submissions require more than technical formatting. They require an understanding of how regulators evaluate evidence, assess risk and weigh benefit claims. That need becomes even more important in rare disease programs, accelerated pathways and medical device development, where designation strategy, trial feasibility and long-term market access can shape company value long before approval decisions are made.
The other issue of importance is the post-approval support of the product. Pharmacovigilance, lifecycle management and planning for regulatory compliance affect the viability and relevance of a product in the marketplace.
Cleracs Consulting stands out as a strong option for biotechnology companies seeking regulatory guidance closely tied to development and commercialization goals. The company supports preclinical strategy, pre-IND planning, IND, NDA and BLA submissions, medical device pathways, health authority interactions, post-approval compliance and pharmacovigilance activities.
Its experience also includes FDA and EMA designation programs such as orphan drug, rare pediatric disease, Fast Track and breakthrough therapy pathways, along with CE Marking support under the European MDR framework.
With a focus on orphan drug strategy, regulatory affairs consulting, drug and medical device development and global market authorization support, Cleracs Consulting offers the kind of practical, development-focused regulatory guidance biotechnology companies increasingly need as scientific innovation and regulatory complexity continue to grow together.
...Read more
Regulatory Consulting Info
Q1
Why is Cleracs Consulting recognized among Top Regulatory Consulting Firms?
Cleracs Consulting is recognized as a leading Regulatory Consulting Firm due to its strong track record in guiding complex drug and device programs through global approval pathways. It has supported multiple IND, NDA and BLA submissions while also securing designations such as Orphan Drug and Fast Track for rare disease programs. Its ability to integrate regulatory strategy with clinical development planning makes it a trusted partner for innovators navigating high-stakes regulatory environments.
Q2
What makes Cleracs Consulting different from other Regulatory Consulting Firms?
Unlike traditional advisory groups, Cleracs Consulting operates as a hands-on Regulatory Consulting Firm that embeds itself into client development programs. It combines regulatory affairs, clinical strategy and market access insight under one framework. This integrated approach allows it to align scientific development with regulatory expectations from early-stage planning through submission, reducing delays and improving the probability of approval success.
Q3
How does Cleracs Consulting support drug development as a Regulatory Consulting Firm?
Cleracs Consulting supports development across the full lifecycle, starting from preclinical strategy and continuing through IND submissions, clinical trial design and final marketing applications. As a Regulatory Consulting Firm, it provides structured guidance for FDA and EMA interactions, helping sponsors prepare meeting packages, define endpoints and design regulatory-compliant studies. This ensures that development programs are aligned with global regulatory expectations from the outset.
Q4
What role does regulatory strategy play in Cleracs Consulting’s services?
Regulatory strategy is central to its work as a Regulatory Consulting Firm. The company develops tailored pathways for each product based on therapeutic area, risk profile and target market. This includes identifying expedited programs such as Breakthrough Therapy or Rare Pediatric Disease Designation when applicable. By structuring regulatory plans early, Cleracs helps reduce rework and supports faster progression toward approval milestones.
Q5
How does Cleracs Consulting ensure global compliance across regions?
Cleracs Consulting operates across multiple jurisdictions including the United States, Europe, UK and other global markets. As a Regulatory Consulting Firm, it ensures that submissions meet region-specific requirements such as FDA, EMA and MHRA standards. Its team includes former regulatory agency professionals who understand both the technical and procedural expectations of different authorities, enabling smoother cross-border approvals.
Q6
Why do biotech and pharmaceutical companies rely on Cleracs Consulting as a Regulatory Consulting Firm?
Companies rely on Cleracs Consulting because it offers both strategic insight and execution capability within one framework. Its Regulatory Consulting Firm model supports not only regulatory submissions but also funding strategy, market access planning and due diligence. This makes it particularly valuable for biotech companies that need structured guidance from early research through commercialization, especially in rare disease and specialty therapy areas.
